VEGFA and macular retinal edema: Here, undesirable events following anti-VEGF treatment were defined as absence of VA improvement due to macular oedema (CST > 325 μm and VA change from baseline <5 ETDRS letters) at 2 consecutive visits or loss of VA attributable to increase in macular oedema (CST increase by 50 μm and loss of at least 10 ETDRS letters from baseline).